iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases.
Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102.
PharmaNest, a leader in high resolution quantitative Digital Pathology and Artificial Intelligence, announces today the launch new quantitative tissue panels to properly quantify tissue injury and inflammation in the context of multiple fibrotic conditions, from discovery models to clinical development. Such spatially resolved datasets can be fused with other spatially resolved biology methods.
Read Press ReleasePharmaNest, a leader in high resolution, single-fiber, quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest Ph-FCS continuous fibrosis biomarker for the quantification of the severity of fibrosis and prognostics of liver related clinical events in NASH.
Read Press ReleaseEMA offers endorsement for AI optimization of clinical trials. Two Owkin AI models significantly improve the discrimination accuracy for overall survival in hepatocellular carcinoma and mesothelioma. Owkin to develop on-demand prognostic scores for other indications to further reduce clinical trial failure rates
Read Press ReleaseFarmaKeio Outsourcing is proud to announce the release of its latest innovation, the only patented hormone pellet with triamcinolone developed in an FDA-registered 503B outsourcing facility. The pellet is set to provide a new and revolutionary solution to hormone replacement therapy for men and women.
Read Press ReleaseRevolutionizing Clinical Trials: Site Enablement League Unites Industry Leaders to Accelerate Cures and Optimize Site Experience
Read Press Release